The archive · Health & Care · Strategic decision · 2024-2026
Adialante bets rentable mobile MRI makes cancer screening annual: $12.75M LOIs
YC S26 spin-out Adialante builds 80%-lighter mobile whole-body MRIs it rents per scan, signing 6 clinics and $12.75M in LOIs before demo day.
Adialante
What the business is
Owns and operates compact whole-body MRI scanners in mobile trailers, charging clinics per scan instead of selling the hardware.
Starting capital：$30,000 in deposits from clinics reserving scanner slots and 'millions' in competitive grants won over six years, per the YC launch post (2026-07-08); Y Combinator and Founder Factor listed as investors.
How it started
Co-founders Efraín Torres and Parker Jenkins, biomedical engineers who met in their engineering dorm, spent six years re-inventing MRI physics, algorithms and hardware, winning competitive grants and securing two US patents (#12,625,209 and #12,372,595). Their redesign uses 50% less hardware, is 40% shorter and 80% lighter, whisper-quiet and free of specialized infrastructure.
What happened
Adialante entered Y Combinator's Spring 2026 batch and, per its July 2026 launch post, had assembled its first MRI, signed 6 clinics, collected $12.75M in letters of intent and taken a $30K deposit from a top-ten urology clinic. TechCrunch's June 2026 Demo Day roundup flagged it as one of 11 standout companies; the model is deliberately Waymo-like - own and operate the scanners rather than sell them, improving the AI software after every scan.
No ending yet — it is still running.
Background
Adialante is a Minneapolis startup, spun out of the University of Minnesota, that has redesigned MRI from first principles to make whole-body scanners compact enough for a small truck: 50% less hardware, 40% shorter, 80% lighter, whisper-quiet and requiring no specialized infrastructure, with two issued US patents behind the approach.
The business model is the actual bet. Instead of selling scanners - which cost millions to buy and tens of thousands a year to maintain - Adialante owns and operates them, bringing an imaging clinic on wheels to doctors and charging per scan (around $250). The clinic collects insurance reimbursement and profits; Adialante keeps recurring revenue and improves its AI software after every scan, in what the founders explicitly compare to Waymo's owned-and-operated fleet.
Adialante is starting with prostate cancer: more than 1 million men a year need an MRI before a prostate biopsy, but virtually none of the urology clinics that treat them can offer one. By July 2026, per its Y Combinator launch post, the company had signed 6 clinics, secured $12.75M in letters of intent for scanner utilization, taken a $30K deposit from a top-ten urology clinic and assembled its first system, with the first scan planned by demo day.
The ambition is to move MRI from a symptomatic exam to routine annual screening for high-risk cancers, then expand the same hardware to renal, breast and brain scanning. TechCrunch's June 2026 survey of eight investors named Adialante one of 11 standout startups from YC's Spring 2026 Demo Day, in a batch where at least two companies fetched valuations of $175M or more.
What has to be true
- The per-scan rental model removes the million-dollar capex that keeps MRIs out of most clinics, changing a capital-purchase decision into an operating expense.
- The wedge is precise: 1M+ men need prostate MRI each year, but almost no urology clinic can provide it - demand already exceeds supply in a niche incumbents ignore.
- Re-engineering the physics (B1/spatial encoding via RF rather than heavy gradient coils) is what makes the 80% weight cut and mobile form factor physically possible.
- Owning the fleet means every scan improves their AI software, so the hardware gets more valuable with each deployment - a data loop a machine seller would never capture.
What can be applied
Sell the outcome, not the asset: per-scan pricing removes the buyer's capex barrier, and starting in urology gave Adialante a wedge where demand already exceeded supply.
Aftermath
As of July 2026 Adialante is at pre-seed stage with a four-person team in Minneapolis, backed by Y Combinator and Founder Factor. Its first whole-body MRI was assembled, six clinics were signed, and LOIs totaled $12.75M with a $30K deposit from a top-ten urology clinic; the first scan was planned for YC demo day. Rollout starts with prostate imaging before expanding to renal, breast and brain, with the long-term goal of routine annual screening for high-risk cancers. Open questions are regulatory clearance, reimbursement economics and competition from established MRI vendors.
Sources
- The 11 standout startups from YC's Demo Day, according to VCs
- Launch YC: Adialante: We're going to screen the world for cancer!
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card